Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Retained Earnings: 2018-2025

Historic Retained Earnings for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to -$879.6 million.

  • Bicycle Therapeutics' Retained Earnings fell 39.86% to -$879.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$879.6 million, marking a year-over-year decrease of 39.86%. This contributed to the annual value of -$680.8 million for FY2024, which is 33.03% down from last year.
  • Per Bicycle Therapeutics' latest filing, its Retained Earnings stood at -$879.6 million for Q3 2025, which was down 7.20% from -$820.5 million recorded in Q2 2025.
  • Bicycle Therapeutics' Retained Earnings' 5-year high stood at -$167.8 million during Q1 2021, with a 5-year trough of -$879.6 million in Q3 2025.
  • Over the past 3 years, Bicycle Therapeutics' median Retained Earnings value was -$578.1 million (recorded in 2024), while the average stood at -$602.3 million.
  • Data for Bicycle Therapeutics' Retained Earnings shows a maximum YoY tumbled of 54.57% (in 2023) over the last 5 years.
  • Bicycle Therapeutics' Retained Earnings (Quarterly) stood at -$218.4 million in 2021, then tumbled by 51.62% to -$331.1 million in 2022, then plummeted by 54.57% to -$511.8 million in 2023, then slumped by 33.03% to -$680.8 million in 2024, then tumbled by 39.86% to -$879.6 million in 2025.
  • Its Retained Earnings was -$879.6 million in Q3 2025, compared to -$820.5 million in Q2 2025 and -$741.5 million in Q1 2025.